Morgan Stanley lowered shares of AstraZeneca plc (LON:AZN) to an equal weight rating in a research note published on Friday morning. They currently have GBX 4,700 ($62.00) target price on the biopharmaceutical company’s stock, down from their previous target price of GBX 5,600 ($73.87).

AZN has been the subject of several other research reports. Beaufort Securities lowered shares of AstraZeneca plc to a sell rating and set a GBX 3,900 ($51.44) target price for the company. in a report on Friday. J P Morgan Chase & Co restated a neutral rating and issued a GBX 4,200 ($55.40) target price (down previously from GBX 5,000 ($65.95)) on shares of AstraZeneca plc in a report on Friday. Kepler Capital Markets set a GBX 5,200 ($68.59) target price on shares of AstraZeneca plc and gave the stock a buy rating in a report on Friday. Citigroup Inc. restated a buy rating and issued a GBX 6,000 ($79.15) target price on shares of AstraZeneca plc in a report on Friday. Finally, Berenberg Bank set a GBX 5,500 ($72.55) target price on shares of AstraZeneca plc and gave the stock a buy rating in a report on Friday. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of Hold and an average price target of GBX 5,046.95 ($66.57).

AstraZeneca plc (AZN) opened at 4571.00 on Friday. The stock’s market cap is GBX 57.87 billion. The firm has a 50 day moving average of GBX 5,140.37 and a 200-day moving average of GBX 4,864.62. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.

COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (LON:AZN) Downgraded by Morgan Stanley to Equal Weight” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/astrazeneca-plc-lonazn-downgraded-by-morgan-stanley-to-equal-weight/1464800.html.

The company also recently disclosed a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be given a GBX 68.90 ($0.91) dividend. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th.

In other news, insider Nazneen Rahman acquired 39 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were purchased at an average price of GBX 4,370 ($57.64) per share, with a total value of £1,704.30 ($2,248.12).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.